Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 19, Issue 1, Pages 37-50
Publisher
Springer Science and Business Media LLC
Online
2021-09-27
DOI
10.1038/s41571-021-00552-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).
- (2021) Gulam Abbas Manji et al. JOURNAL OF CLINICAL ONCOLOGY
- Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion
- (2021) Nicole E. Scharping et al. NATURE IMMUNOLOGY
- CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
- (2021) Roberta Zappasodi et al. NATURE
- Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
- (2021) McLane J. Watson et al. NATURE
- Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
- (2021) Rebekka Duhen et al. Nature Communications
- Analysis of OX40 agonist antibody (PF-04518600) in patients with hepatocellular carcinoma.
- (2020) Anthony B. El-Khoueiry et al. JOURNAL OF CLINICAL ONCOLOGY
- FS222, a CD137/PD-L1 tetravalent bispecific antibody exhibits low toxicity and anti-tumor activity in colorectal cancer models
- (2020) Matthew A Lakins et al. CLINICAL CANCER RESEARCH
- Obesity and CD8 T cell metabolism: Implications for anti‐tumor immunity and cancer immunotherapy outcomes
- (2020) William J. Turbitt et al. IMMUNOLOGICAL REVIEWS
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- (2020) Delvys Rodriguez-Abreu et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.
- (2020) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
- (2020) Zhilin Zou et al. Cell and Bioscience
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases
- (2020) Wiwin Is Effendi et al. Cells
- Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
- (2020) Mark R. Middleton et al. BRITISH JOURNAL OF CANCER
- Metabolic signaling in T cells
- (2020) Justin A. Shyer et al. CELL RESEARCH
- Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial
- (2020) Shuhong Wang et al. CLINICAL CANCER RESEARCH
- Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen
- (2020) Santosha A. Vardhana et al. NATURE IMMUNOLOGY
- The adenosine pathway in immuno-oncology
- (2020) Bertrand Allard et al. Nature Reviews Clinical Oncology
- Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
- (2020) Lawrence P. Andrews et al. Science Immunology
- LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
- (2020) I-M. Svane et al. ANNALS OF ONCOLOGY
- 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
- (2020) M-J. Ahn et al. ANNALS OF ONCOLOGY
- First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
- (2020) Ravit Geva et al. CANCER
- Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
- (2020) Ani S. Balmanoukian et al. CLINICAL CANCER RESEARCH
- An antibody targeting ICOS increases intratumoral cytotoxic to regulatory T cell ratio and induces tumor regression
- (2020) Richard C.A. Sainson et al. Cancer Immunology Research
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- Rational design of anti-GITR-based combination immunotherapy
- (2019) Roberta Zappasodi et al. NATURE MEDICINE
- The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
- (2019) Anne Månsson Kvarnhammar et al. Journal for ImmunoTherapy of Cancer
- Characterization and comparison of GITR expression in solid tumors
- (2019) Luis Vence et al. CLINICAL CANCER RESEARCH
- 4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8 + T cells in Hepatocellular Carcinoma
- (2019) Hyung‐Don Kim et al. HEPATOLOGY
- In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors
- (2019) Danny N. Khalil et al. JOURNAL OF CLINICAL INVESTIGATION
- Immune checkpoints in the tumor microenvironment
- (2019) Salman M. Toor et al. SEMINARS IN CANCER BIOLOGY
- OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function
- (2019) Fanny Polesso et al. JOURNAL OF IMMUNOLOGY
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1119PDInducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)
- (2019) D Rischin et al. ANNALS OF ONCOLOGY
- Metabolic Consequences of T-cell Costimulation in Anticancer Immunity
- (2019) Alvaro Teijeira et al. Cancer Immunology Research
- Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors
- (2019) Kimberley M. Heinhuis et al. JAMA Oncology
- Reprogramming of fatty acid metabolism in cancer
- (2019) Nikos Koundouros et al. BRITISH JOURNAL OF CANCER
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer
- (2018) Lifeng Li et al. CANCER RESEARCH
- Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
- (2018) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
- (2018) Cristina Gutiérrez-Vázquez et al. IMMUNITY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Safety of combining radiotherapy with immune-checkpoint inhibition
- (2018) William L. Hwang et al. Nature Reviews Clinical Oncology
- The promise and challenges of immune agonist antibody development in cancer
- (2018) Patrick A. Mayes et al. NATURE REVIEWS DRUG DISCOVERY
- Prostate cancer: Enhancing VTP
- (2018) Clemens Thoma Nature Reviews Urology
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma
- (2018) Lukas Krähenbühl et al. NEOPLASIA
- A Landscape of Metabolic Variation across Tumor Types
- (2018) Ed Reznik et al. Cell Systems
- Targeting adenosine for cancer immunotherapy
- (2018) Robert D. Leone et al. Journal for ImmunoTherapy of Cancer
- ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
- (2018) Timothy Anthony Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
- (2018) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.
- (2018) Ravit Geva et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
- (2018) Ben Tran et al. Journal for ImmunoTherapy of Cancer
- Putting the Immunologic Brakes on Cancer
- (2018) Jedd Wolchok CELL
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Tim-3 expression and its role in hepatocellular carcinoma
- (2018) Feifei Liu et al. Journal of Hematology & Oncology
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
- (2017) Andrew W Hahn et al. Immunotherapy
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
- (2017) Nicholas A. Manieri et al. TRENDS IN IMMUNOLOGY
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
- (2016) C. Coyle et al. ANNALS OF ONCOLOGY
- Rationale for anti-GITR cancer immunotherapy
- (2016) Deborah A. Knee et al. EUROPEAN JOURNAL OF CANCER
- Emerging concepts of T cell metabolism as a target of immunotherapy
- (2016) Chih-Hao Chang et al. NATURE IMMUNOLOGY
- Pathological -synuclein transmission initiated by binding lymphocyte-activation gene 3
- (2016) X. Mao et al. SCIENCE
- Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
- (2016) Nicole E. Scharping et al. Cancer Immunology Research
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
- (2015) T. Kouo et al. Cancer Immunology Research
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells
- (2013) Kai Wang et al. CANCER LETTERS
- CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
- (2013) Q. Ye et al. CLINICAL CANCER RESEARCH
- AhR expression is increased in hepatocellular carcinoma
- (2013) Ziyu Liu et al. JOURNAL OF MOLECULAR HISTOLOGY
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Tolerance and exhaustion: defining mechanisms of T cell dysfunction
- (2013) Andrea Schietinger et al. TRENDS IN IMMUNOLOGY
- GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
- (2013) D. A. Schaer et al. Cancer Immunology Research
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti-CTLA-4 Therapy
- (2011) R. Waitz et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- CD47-signal regulatory protein- (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction
- (2011) X. W. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective Depletion of CD4+CD25+Foxp3+Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP Levels
- (2010) Jie Zhao et al. CANCER RESEARCH
- Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines
- (2010) Brett C. DiNatale et al. MOLECULAR CARCINOGENESIS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
- (2009) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started